MEIJI

Meiji Biopharmaceutical (Guangzhou) Co., Ltd. is an emerging pharmaceutical company centered on an internationally leading next-generation self-emulsifying liposome nanoparticle (SELNP) delivery technology platform. It is committed to the independent research and development of improved new drugs and biological macromolecule new drugs, providing "high cost-effective" therapeutic drugs to meet unfulfilled global medical and health needs. Our mission is to provide efficient and safe new therapies through groundbreaking innovations, addressing industry pain points in global clinical applications. The core R&D pipeline focuses on areas such as cancer, diabetes, obesity, non-alcoholic steatohepatitis, rheumatoid arthritis, and anesthesia analgesia.